Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bionet Corp. (1784:TWSE), powered by AI.
Bionet Corp. is currently trading at $66.00. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Bionet Corp. on Alpha Lenz.
View Bionet Corp.'s valuation metrics on Alpha Lenz.
“Bionet Corp.'s ROE is 3.9%. Explore profitability and growth together.”
Ask for details →Bionet Corp. is a biotechnology company based in Taipei, Taiwan, specializing in cell therapy, regenerative medicine, and medical big data. Its core businesses encompass stem cell banking—offering storage and applications for various types of stem cells, including mesenchymal, dental, adipose, peripheral blood, and immune cells—as well as genetic and prenatal testing services. The company is also engaged in the development of regenerative medical solutions, such as novel anti-aging therapies and the ANIKINE product line, and is pioneering cell-free treatments like exosome therapy. Beyond these, Bionet provides analytical testing, R&D, and commercializes cell-derived medical products, serving both local and international healthcare markets. Founded in 1989, Bionet Corp. plays an important role in advancing biotechnology capabilities in Taiwan, contributing to developments in diagnostics, therapeutic applications, and health technology innovation for the broader healthcare sector.
“Bionet Corp.'s ROE is 3.9%. Explore profitability and growth together.”
Ask for details →Bionet Corp. (ticker: 1784) is a company listed on TWSE in the Healthcare sector (Diagnostics & Research).
The current price is 66 with a P/E ratio of -x and P/B of -x.
ROE is 3.95% and operating margin is -0.98%. Annual revenue is $1.2B.